BHC — Bausch Health Companies Inc.

Bausch Health (BHC) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Consolidated Revenue: $2.681 billion, up 7% year-over-year (5% organic growth).
• Adjusted EBITDA: $986 million, an 8% increase year-over-year; adjusted EBITDA for Bausch Health excluding Bausch + Lomb was $773 million, up 7% (18% growth excluding an $81 million R&D charge).
• Adjusted Operating Cash Flow: $508 million overall; $347 million for Bausch Health excluding Bausch + Lomb, a 1% increase year-over-year.
• Debt Reduction: Approximately $600 million reduced through cash on hand and strong performance in the first nine months.
• New Full-Year Guidance: Revenue expected between $5 billion and $5.1 billion; adjusted EBITDA between $2.7 billion and $2.75 billion; adjusted operating cash flow between $975 million and $1.025 billion.

2. Strategic Updates and Business Highlights

• 10th Consecutive Quarter of Growth: Bausch Health, excluding Bausch + Lomb, achieved consistent revenue and adjusted EBITDA growth.
• Key Growth Segments:
  • Salix: Revenue of $716 million, up 12% driven by Xifaxan's volume growth (16% increase).
  • Solta Medical: Revenue of $140 million, up 25%, with strong performance in the Asia Pacific region, particularly South Korea.
• Product Highlights: Notable growth in Xifaxan, Cabtreo (186% growth), and Ryaltris, with a focus on marketing and operational excellence.
• Acquisition of DURECT Corporation: Completed on September 11, 2025, enhancing the R&D pipeline, particularly in hepatology.

3. Forward Guidance and Outlook

• Increased Guidance: Reflecting strong performance, BHC raised its revenue, adjusted EBITDA, and cash flow guidance for the full year.
• Long-term Strategy: Focus on operational excellence, innovation, and unlocking shareholder value while managing capital structure and debt.

4. Bad News, Challenges, or Points of Concern

• International Segment Decline: Revenue decreased by 2% on a reported basis, with mixed performance across geographies; Canada and Latin America showed significant contractions.
• Pricing Dynamics: Xifaxan's revenue growth outpaced script growth due to a one-time pricing benefit related to inventory adjustments and exit from the 340B program.
• Medicare Pricing Negotiations: Ongoing discussions with CMS regarding Xifaxan pricing, with potential impacts expected post-2025.
• SG&A Spending: Lower SG&A in Q3 attributed to nonrecurring accrual adjustments, raising concerns about future spending consistency.

5. Notable Q&A Insights

• Xifaxan Growth: The disconnect between revenue growth and script growth was attributed to pricing adjustments and strong new patient starts, with a focus on direct-to-consumer marketing.
• CMS Negotiations: The company is optimistic about negotiations with CMS, expecting agreed pricing to be published on November 30, 2025.
• Debt Management: Future deleveraging strategies include using free cash flow and potential asset sales, particularly regarding Bausch + Lomb.
• Pipeline Developments: Anticipation of Phase III results for RED-C in early 2026, with discussions on the importance of primary and secondary endpoints for future regulatory filings.

Overall, Bausch Health demonstrated strong operational performance in Q3 2025, with strategic growth in key segments, but faces challenges in international markets and ongoing pricing negotiations that could impact future performance.